WO2013167112A1 - Komposition für nasale anwendung - Google Patents
Komposition für nasale anwendung Download PDFInfo
- Publication number
- WO2013167112A1 WO2013167112A1 PCT/DE2013/000261 DE2013000261W WO2013167112A1 WO 2013167112 A1 WO2013167112 A1 WO 2013167112A1 DE 2013000261 W DE2013000261 W DE 2013000261W WO 2013167112 A1 WO2013167112 A1 WO 2013167112A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substances
- pharmaceutical composition
- nervous system
- central nervous
- acting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Definitions
- composition for nasal application Composition for nasal application
- the invention relates to a pharmaceutical composition for a nasal application, in which substances act on the central nervous system, and substance-assistants, which act on the structures of the mucous membrane of the nasal cavity and are intended for an active action on the regulatory centers of the brain.
- This invention is intended for stationary and private use and at the same time is easy to use.
- Many biologically active molecules from the external environment and from the internal environment of the organism are useful and necessary for maintaining the physiological functions of organs and tissues, including the brain and the central nervous system (CNS) as a whole. These include, for example, the majority of medications and many biochemical compounds - products of metabolism that arise in the organism through metabolism.
- the biologically active molecules including regulatory substance metabolites, are said to penetrate the structures of the brain through the multiple biological membranes, the least permeable of which are the brain-blood barrier complexes.
- Ming Ming Wen (201 1) describes the delivery of drugs from the nasal cavity to the brain using a variety of techniques, in particular the use of mucoadhesive agents to enhance the drug's contact with the nasal mucus, as well as the use of penetrating enhancers , Liposomes, Nanoparticles and Other Methods (Ming Ming Wen (2011) Intranasal Delivery - Physicochemical and Therapeutic Aspects, International Journal of Pharmaceutics 337, 1-24). Although the proposed methods allow small molecules of drugs to penetrate into the brain, these methods are not universally suitable for delivery to the brain for a wide range of drug substances.
- Known nasally introduced drugs reach the brain from the nasal cavity thanks to both the anatomical connections of the elements of the olfactory system and the trigeminal nerve. Nevertheless, despite direct connection of peripheral elements of an olfactory system with a brain, efficiency of delivery to a brain of nasally administered drugs is very limited, that is connected in particular with the limited surface of the olfactory epithelium, which is less than 8% of the surface of nasal cavity mucous membrane forms.
- a modern approach to solving the problem of delivery of drugs to the brain is the use of some low molecular weight substances of a free radical nature.
- the inhaled application of active oxygen radicals is known for increasing the analgesic pain-killing effects introduced into the body by one of the traditional routes, such as oral or by injection ⁇ Goldstein, N., Lewin, T., Kamensky, A., Dubinin V., Baumann, S., Konstantinova, O. (1996) Exogenous gaseous superoxide potentiates the antinociceptive effect of opioid analgesic agents. Inflamm. Res., 5, 473-478).
- Patent DE 19514 522 describes a pharmaceutical composition for the treatment of pain consisting of an analgesic for the treatment of severe pain, as well as Oxygen radicals and / or products of their transformations or decay.
- a deficiency in the patent DE 195 14 522 is the limited therapeutic effectiveness.
- Another deficiency is the limited clinical applicability associated with difficulties of separate oral or injection administration of a drug and nasal induction of SAR.
- Patent RU N ° 2253461 describes the enhancement of the therapeutic efficacy of medicinal substances by a pharmaceutical combination in which the function of the CNS is influenced, whereby at least one substance is contained which has a healing effect on the CNS and differs in that as the substance contributing to penetration through the brain blood barrier acts via reflector-preferential neuro- and vasodilatory action on the structures and receptors of the nasal cavity mucosa, mainly the receptors of the vomeronasal organs and the trigeminal nerve.
- experience has shown that increasing the effectiveness of the drugs for various biological substances is substantially different in the pharmaceutical combination described in patent RU Na 2253461, which makes the practical application considerably more complicated.
- Eurasian patent .No. 10692 describes the pharmaceutical agent for nasal application for the treatment of diseases and disorders of the central nervous system using a mixture containing biologically active substances acting on the central nervous system and such substances, which act on the mucosa of the nose using the oxygen anion radicals and / or the active products of the nitric oxide.
- the use of the described spray (see item 14 of the formula) consists of a mixture of biologically active substances which act on the central nervous system and consist of substances which are concentrated on the nasal mucosa such as oxygen anion. Radical and / or active products of the nitrogen oxide act.
- the object of the invention is to increase the effectiveness of the medicaments, metabolites and / or other previously described types of active substances that are used for the treatment of diseases and disorders of the central nervous system and the reduction of the usual dosage of the drugs used, as well as the achievement of a faster and prolonged effect.
- substances refers to one or more medicinal substances, metabolites and / or previously described types of biologically active substances which are used for the treatment of diseases and disorders of the CNS.
- Assistants are meant to be used alone or together with the other active oxygen radicals (SAR) and their conversion or other applied products such as superoxide ion (0 2 * ⁇ ), singlet oxygen ( ⁇ 2 ), hydroxyl radical (HO ' ) , perhydroxyl radical ( ⁇ 0 2 '), hydrogen peroxide (H 2 0 2), individually or together with nitrogen sources (NO- products) as the sources of active nitrogen oxide nO enumerated but not limited L- arginine, isosorbide mononitrate, nitroprusside, Penthaerythril tetranitrate or glycerol tetranitrate.
- SAR active oxygen radicals
- NO- products nitrogen sources
- the pharmaceutical composition described in the invention contains biologically active substances which are biologically active substances and metabolites, for example from the classes of the agonists dopaminergic receptors, narcotic and non-narcotic analgesics, antiepileptic drugs from the group of barbiturates, as well as from a helper, containing free radical forms of anion radicals of oxygen or their conversion products (ROS), for example hydrogen peroxide, and pharmacologically acceptable active nitrogen oxide (NO) products.
- ROS free radical forms of anion radicals of oxygen or their conversion products
- NO active nitrogen oxide
- IEE IEE Index
- composition-1 dopamine-containing pharmaceutical composition
- Dopamine / hydrogen peroxide / L-arginine Group IV
- dopamine-containing pharmaceutical agent according to the Eurasian patent N ° 010692 (group III)
- the studied feature is the duration of catalepsy caused by intraperitoneal (ip) injection of the haloperidol.
- Example 1 Table 1
- Eurasian Patent O 10692 the higher effectiveness of the application of the composition explained here from the assistant and the dopamine according to the formula has been demonstrated.
- Insufficient effectiveness of the pharmaceutical agent according to Eurasian Patent O 10692 could be caused by a cross-interaction of the substances contained in the spray.
- the characteristics studied are based on the intensity of the critical pressure (IKD) on the hind paws of the rats and the duration of the analgesic action.
- the number of animals in each group 10.
- composition-2 The positive effects of the declared pharmaceutical "Composition-2" are also valid for the substances found in the brain in the usual ways of use as well penetrating, in which case the increase of efficiency is expressed in significant reduction of a dose of biologically active substances (Example 4).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/399,773 US20150165033A1 (en) | 2012-05-09 | 2013-05-06 | Composition for nasal application |
EA201492045A EA201492045A1 (ru) | 2012-05-09 | 2013-05-06 | Композиция для назального применения |
CN201380036858.7A CN104582690A (zh) | 2012-05-09 | 2013-05-06 | 用于经鼻部施用的组合物 |
SG11201505178VA SG11201505178VA (en) | 2012-05-09 | 2013-05-06 | Composition for nasal application |
EP13732077.6A EP2846771A1 (de) | 2012-05-09 | 2013-05-06 | Komposition für nasale anwendung |
JP2015510645A JP2015519332A (ja) | 2012-05-09 | 2013-05-06 | 鼻腔適用のための組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012009570.8 | 2012-05-09 | ||
DE102012009570A DE102012009570A1 (de) | 2012-05-09 | 2012-05-09 | Komposition für nasale Anwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013167112A1 true WO2013167112A1 (de) | 2013-11-14 |
WO2013167112A8 WO2013167112A8 (de) | 2014-01-23 |
Family
ID=48700230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2013/000261 WO2013167112A1 (de) | 2012-05-09 | 2013-05-06 | Komposition für nasale anwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150165033A1 (de) |
EP (1) | EP2846771A1 (de) |
JP (1) | JP2015519332A (de) |
CN (1) | CN104582690A (de) |
DE (1) | DE102012009570A1 (de) |
EA (1) | EA201492045A1 (de) |
SG (1) | SG11201505178VA (de) |
WO (1) | WO2013167112A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014023288A1 (de) * | 2012-08-05 | 2014-02-13 | Naum Goldstein | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19514522C1 (de) | 1995-04-12 | 1996-06-13 | Goldstein & Lewin Tech Gmbh | Sauerstoffanionradikale enthaltende therapeutische Mittel und deren Verwendung zur Schmerzbehandlung |
WO2004037291A1 (de) * | 2002-10-17 | 2004-05-06 | Naum Goldstein | Pharmazeutisches mittel zur endonasalen applikation bei der behandlung von krankheiten und störungen des zentralen nervensystems |
US20050048002A1 (en) | 2003-06-24 | 2005-03-03 | Barrett Rabinow | Method for delivering drugs to the brain |
RU2253461C1 (ru) | 2004-04-30 | 2005-06-10 | Общество с ограниченной ответственностью "Паркинфарм" | Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения |
WO2009086470A2 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2610602B1 (fr) * | 1987-02-09 | 1989-07-21 | Sofab Ste Fse Aerosol Bouchage | Conditionnement melangeur distributeur |
US5437267A (en) * | 1993-08-03 | 1995-08-01 | Weinstein; Allan | Device for delivering aerosol to the nasal membranes and method of use |
ATE374607T1 (de) * | 1994-05-27 | 2007-10-15 | Strakan Int Ltd | Zusammensetzung enthaltend stickstoffoxid- donatoren und methode zur behandlung analer krankheiten |
US6544971B1 (en) * | 2000-02-04 | 2003-04-08 | Pherin Pharmaceuticals, Inc. | Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
KR100632458B1 (ko) * | 2004-04-30 | 2006-10-11 | 아이치 세이코우 가부시키가이샤 | 가속도 센서 |
DE102012015248A1 (de) * | 2012-08-05 | 2014-02-06 | Naum Goldstein | Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn |
-
2012
- 2012-05-09 DE DE102012009570A patent/DE102012009570A1/de not_active Withdrawn
-
2013
- 2013-05-06 EP EP13732077.6A patent/EP2846771A1/de not_active Withdrawn
- 2013-05-06 CN CN201380036858.7A patent/CN104582690A/zh active Pending
- 2013-05-06 SG SG11201505178VA patent/SG11201505178VA/en unknown
- 2013-05-06 WO PCT/DE2013/000261 patent/WO2013167112A1/de active Application Filing
- 2013-05-06 US US14/399,773 patent/US20150165033A1/en not_active Abandoned
- 2013-05-06 EA EA201492045A patent/EA201492045A1/ru unknown
- 2013-05-06 JP JP2015510645A patent/JP2015519332A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19514522C1 (de) | 1995-04-12 | 1996-06-13 | Goldstein & Lewin Tech Gmbh | Sauerstoffanionradikale enthaltende therapeutische Mittel und deren Verwendung zur Schmerzbehandlung |
WO2004037291A1 (de) * | 2002-10-17 | 2004-05-06 | Naum Goldstein | Pharmazeutisches mittel zur endonasalen applikation bei der behandlung von krankheiten und störungen des zentralen nervensystems |
EA010692B1 (ru) | 2002-10-17 | 2008-10-30 | Наум Гольдштейн | Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений центральной нервной системы |
US20050048002A1 (en) | 2003-06-24 | 2005-03-03 | Barrett Rabinow | Method for delivering drugs to the brain |
RU2253461C1 (ru) | 2004-04-30 | 2005-06-10 | Общество с ограниченной ответственностью "Паркинфарм" | Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения |
WO2009086470A2 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
Non-Patent Citations (4)
Title |
---|
GOLDSTEIN N ET AL: "Blood-brain barrier unlocked", BIOCHEMISTRY (MOSCOW), KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 77, no. 5, 16 May 2012 (2012-05-16), pages 419 - 424, XP035057140, ISSN: 1608-3040, DOI: 10.1134/S000629791205001X * |
GOLDSTEIN, N.; LEWIN, T; KAMENSKY, A.; DUBININ V; BAUMANN, S.; KONSTANTINOVA, O.: "Exogenous gaseous superoxide potentiates the antinociceptive effect of opioid analgesic agents", INFLAMM. RES., vol. 5, 1996, pages 473 - 478, XP002081033 |
MING MING WEN: "Intranasal delivery - physicochemical and therapeutic aspects", INTERNATIONAL JOURNAL 01 PHARMACEUTICS, vol. 337, 2011, pages 1 - 24, XP022085247, DOI: doi:10.1016/j.ijpharm.2007.03.025 |
See also references of EP2846771A1 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014023288A1 (de) * | 2012-08-05 | 2014-02-13 | Naum Goldstein | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn |
Also Published As
Publication number | Publication date |
---|---|
DE102012009570A1 (de) | 2013-11-14 |
US20150165033A1 (en) | 2015-06-18 |
JP2015519332A (ja) | 2015-07-09 |
EA201492045A1 (ru) | 2015-04-30 |
SG11201505178VA (en) | 2015-08-28 |
WO2013167112A8 (de) | 2014-01-23 |
CN104582690A (zh) | 2015-04-29 |
EP2846771A1 (de) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170290778A1 (en) | Compositions for topical application of compounds | |
DE602004012403T2 (de) | Zusammensetzungen zur beeinflussung des gewichtsverlusts | |
EP0065747A1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
KR20120092152A (ko) | 타액선 기능장애의 치료 | |
DE1792410B2 (de) | Arzneimittelzubereitung zur intravenösen Injektion | |
EP2385835A1 (de) | Verwendung von deuteriumoxid zur behandlung virus-basierter erkrankungen des auges | |
US20230414563A1 (en) | Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and addictive disorders | |
DE69629108T2 (de) | Anwendung von ketamin zur entgiftung | |
DE202023001867U1 (de) | Formulierung umfassend mindestens eine Kresse-Art | |
EP2846771A1 (de) | Komposition für nasale anwendung | |
DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
DE60206169T2 (de) | Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff | |
EP0204737B1 (de) | Präparat zur intramuskulären injektion von medikamenten, vitaminen oder impfstoffen | |
DE19612504C2 (de) | Neue Wirkstoffkompositionen | |
EP2818167A1 (de) | Antiviral wirksame pharmazeutische Zusammensetzung | |
EP1408968B1 (de) | Rezeptoradaptierter nikotinentzug durch eine kombination von atropin, scopolamin, clonidin | |
DE10238161A1 (de) | Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation | |
RU2506090C1 (ru) | Средство, обладающее адаптогенной активностью | |
Nagati et al. | Study of the effect of Nigella Sativa oil and its loaded nanoparticles on acute cystic Echinoncoccosis in experimentally infected mice | |
EP2863887B1 (de) | Emulsion zur pharmazeutischen anwendung und verfahren zu deren herstellung | |
RU2305552C2 (ru) | Средство, обладающее кроветворным действием | |
WO2014023288A1 (de) | Verfahren zur einbringung biologisch aktiver substanzen ins gehirn | |
DE102015002709A1 (de) | Neue Verwendung von Acetylsalicylsäure und einem Derivat davon | |
DE202024100422U1 (de) | Nanopartikel-Abgabesystem für Diabetes-Medikamente und dessen Zusammensetzung | |
CN1879637B (zh) | 一种治疗心脑血管病的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13732077 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015510645 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120130023911 Country of ref document: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013732077 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013732077 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201492045 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14399773 Country of ref document: US |